Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from NRX Pharmaceuticals ( (NRXP) ) is now available.
On January 15, 2025, NRx Pharmaceuticals appointed Mike Taylor to its Board of Directors following Janet Rehnquist’s resignation. Taylor’s appointment aligns with a term sheet agreement involving JGS Holdings LLC, which includes a $25 million investment in HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, and the purchase of NRx Pharmaceuticals’ common stock. Additionally, on January 21, 2025, NRx Pharmaceuticals announced that it regained compliance with Nasdaq’s minimum market value requirement, ensuring continued listing on the Nasdaq Capital Market. This development marks a significant milestone for the company, enhancing its market position and providing stability for stakeholders.
More about NRX Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal bipolar depression, chronic pain, and PTSD. The company is advancing its NMDA platform, with NRX-101 being a notable investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain.
YTD Price Performance: 18.06%
Average Trading Volume: 1,086,253
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $42.69M
Learn more about NRXP stock on TipRanks’ Stock Analysis page.
